CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenues:
Total revenues	$ 730	$ 2,498	$ 1,424	$ 2,654
Operating expenses:
Research and development	54,196	39,687	106,810	71,348
General and administrative	10,391	9,128	21,211	18,231
Total operating expenses	64,587	48,815	128,021	89,579
Operating loss	(63,857)	(46,317)	(126,597)	(86,925)
Investment and other income, net	7,257	10,475	16,201	18,275
Net loss	$ (56,600)	$ (35,842)	$ (110,396)	$ (68,650)
Basic net loss per common share (in dollars per share)	$ (0.85)	$ (0.54)	$ (1.66)	$ (1.1)
Diluted net loss per common share (in dollars per share)	$ (0.85)	$ (0.54)	$ (1.66)	$ (1.1)
Shares used in calculating basic net loss per share (in shares)	66,392	66,019	66,388	62,445
Shares used in calculating diluted net loss per share (in shares)	66,392	66,019	66,388	62,445
Comprehensive loss:
Net loss	$ (56,600)	$ (35,842)	$ (110,396)	$ (68,650)
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities	(229)	(464)	25	(1,528)
Comprehensive loss	(56,829)	(36,306)	(110,371)	(70,178)
Product development and licensing agreements
Revenues:
Total revenues	7		57	2
Contracts and grants
Revenues:
Total revenues	$ 723	$ 2,498	$ 1,367	$ 2,652